Compounds > 4-(2-Amino-1,3-thiazol-4-yl)phenol
Page last updated: 2024-12-08

4-(2-Amino-1,3-thiazol-4-yl)phenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID346926
CHEMBL ID483790
CHEBI ID194604
SCHEMBL ID5321407

Synonyms (44)

Synonym
STK723345
BB 0258249
SDCCGMLS-0065861.P001
OPREA1_415030
AE-641/01182060
4-(2-amino-1,3-thiazol-4-yl)phenol
nsc405294
57634-55-6
nsc-405294
4-(2-amino-thiazol-4-yl)-phenol
92G ,
AKOS000303315
DB07292
CHEMBL483790 ,
CHEBI:194604
4-(2-aminothiazol-4-yl)phenol
bdbm50293592
A831534
EN300-81724
2-amino-4-(4-hydroxyphenyl)thiazole
2-amino-4-(4-hydroxyphenyl)-thiazole
FT-0677313
F0370-0333
4-(2-amino-4-thiazolyl)phenol
SCHEMBL5321407
3FU3
SY012597
mfcd01624171
FS-1402
phenol, 4-(2-amino-4-thiazolyl)-
4-(2-amino-1,3-thiazol-4-yl)phenol #
p-(2-amino-4-thiazolyl)phenol
HMS3604B06
sr-01000492488
SR-01000492488-1
CS-0096820
DTXSID30323956
4-(2-amino-1,3-thiazol-4-yl)phenol, aldrichcpr
MLP0GI2196 ,
unii-mlp0gi2196
Q27096518
AMY319
PD005376
Z227972914
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Chain A, Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,443.0000212.00001,235.33332,000.0000AID977608
Fructose-1,6-bisphosphatase 1Sus scrofa (pig)IC50 (µMol)1.10001.10001.32501.6000AID419859
Leukotriene A-4 hydrolaseHomo sapiens (human)IC50 (µMol)1,221.50000.00051.28547.6500AID420374; AID420375
MAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)IC50 (µMol)57.00000.00701.11693.0100AID1582589
MAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)IC50 (µMol)60.00000.00700.95946.2700AID1582590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
proteolysisLeukotriene A-4 hydrolaseHomo sapiens (human)
lipid metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to zinc ionLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene biosynthetic processLeukotriene A-4 hydrolaseHomo sapiens (human)
protein metabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
peptide catabolic processLeukotriene A-4 hydrolaseHomo sapiens (human)
response to peptide hormoneLeukotriene A-4 hydrolaseHomo sapiens (human)
type I pneumocyte differentiationLeukotriene A-4 hydrolaseHomo sapiens (human)
regulation of translationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein phosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
intracellular signal transductionMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein autophosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
regulation of translationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cell surface receptor signaling pathwayMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
hemopoiesisMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
intracellular signal transductionMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to arsenic-containing substanceMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein autophosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
RNA bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
epoxide hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
leukotriene-A4 hydrolase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
protein bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
peptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
zinc ion bindingLeukotriene A-4 hydrolaseHomo sapiens (human)
tripeptide aminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
metalloaminopeptidase activityLeukotriene A-4 hydrolaseHomo sapiens (human)
protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
metal ion bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calmodulin bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
ATP bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
metal ion bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein serine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calmodulin bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
extracellular regionLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleoplasmLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
extracellular exosomeLeukotriene A-4 hydrolaseHomo sapiens (human)
tertiary granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
ficolin-1-rich granule lumenLeukotriene A-4 hydrolaseHomo sapiens (human)
cytosolLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleusLeukotriene A-4 hydrolaseHomo sapiens (human)
nucleoplasmMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cytosolMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cytoplasmMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
nucleusMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
nucleoplasmMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nuclear bodyMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
PML bodyMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nucleusMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1196570Binding affinity to protein kinase (unknown origin) at 200 uM by surface plasmon resonance method2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold.
AID397259Inhibition of Trypanosoma brucei pteridine reductase 1 at 100 uM2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening.
AID1196566Binding affinity to oxidoreductase 1 (unknown origin) at 200 uM by surface plasmon resonance method2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold.
AID1582589Inhibition of N-terminal GST-tagged MNK1 (unknown origin) (37 to 341 residues) expressed in Escherichia coli BL21 (DE3) cells using 5-FAM-TATKSGSTTKNRFVV-NH2 peptide as substrate preincubated with enzyme for 10 mins followed by substrate addition after 602020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.
AID1196567Binding affinity to Plasmodium falciparum AMA1 at 200 uM by surface plasmon resonance method2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold.
AID1196569Binding affinity to carbonic anhydrase 2 (unknown origin) at 200 uM by surface plasmon resonance method2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold.
AID420376Inhibition of ionomycin-stimulated LTB4 production in human whole blood treated 15 mins prior to ionomycin challenge measured after 30 mins of stimulation by enzyme-linked immunosorbent assay2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.
AID1196568Binding affinity to SPSB2 (unknown origin) at 200 uM by surface plasmon resonance method2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold.
AID1196565Binding affinity to oxidoreductase 2 (unknown origin) at 200 uM by surface plasmon resonance method2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold.
AID419859Inhibition of pig FBPase expressed in Escherichia coli EK1601 by spectrophotometry2009Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11
A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase.
AID420374Inhibition of peptidase activity of human recombinant LTA4H expressed in Escherichia coli BL21-AI/pRARE2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.
AID420373Solubility in methanol2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.
AID420375Inhibition of hydrolase activity of human recombinant LTA4H expressed in Escherichia coli BL21-AI/pRARE assessed as LTB4 formation by tandem quadrupole mass spectrometry2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.
AID1582590Inhibition of N-terminal GST-tagged MNK2 (unknown origin) (72 to 385 residues) expressed in Escherichia coli BL21 (DE3) cells using 5-FAM-TATKSGSTTKNRFVV-NH2 peptide as substrate preincubated with enzyme for 10 mins followed by substrate addition after 602020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.63 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenosine monophosphate
Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.		2.0510adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
2-aminobenzimidazole
2-aminobenzimidazole: metabolite of benomyl; RN given refers to parent cpd. 2-aminobenzimidazole : A member of the class of benzimidazoles that is benzimidazole in which the hydrogen at position 2 is replaced by an amino group.		2.0510benzimidazolesmarine xenobiotic metabolite
5-hydroxyindole
[no description available]		2.0510hydroxyindoleshuman metabolite
phenthiazamine
phenthiazamine: RN given refers to parent cpd		2.4820
5-fluoroindole
[no description available]		2.0510fluoroindole
ubenimex
ubenimex: growth inhibitor		2.0510
5-chloroindole
5-chloroindole: a positive allosteric modulator of the 5-HT3 receptor		2.0510
dihydroresveratrol
dihydroresveratrol: structure in first source. dihydroresveratrol : A stilbenol that is 1,1'-ethane-1,2-diyldibenzene with hydroxy groups at positions 1, 3 and 4'.		2.0510stilbenolplant metabolite;
xenobiotic metabolite
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		2.0510resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
4-[(4-phenyl-2-thiazolyl)amino]benzenesulfonamide
[no description available]		2.0510sulfonamide
4-(3-fluorophenyl)-2-thiazolamine
[no description available]		2.1110thiazoles
3-(2-methylpropylthio)-1H-1,2,4-triazol-5-amine
[no description available]		2.0510aryl sulfide
2,4-Di(3-pyridyl)-1,3-thiazole
[no description available]		2.2510thiazoles
mb 05032
[no description available]		2.0510
nvp-ast487
NVP-AST487: antineoplastic; a RET kinase inhibitor that blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells		2.2510
n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
merestinib: in phase I clinical trials (2013); structure in first source		2.2510
ConditionIndicatedRelationship StrengthStudiesTrials